Technical Analysis for BDRX - Biodexa Pharmaceuticals plc

Grade Last Price % Change Price Change
F 3.85 7.24% 0.26
BDRX closed up 7.24 percent on Wednesday, November 20, 2024, on 16 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
Lower Bollinger Band Walk Weakness 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish 7.24%
Narrow Range Bar Range Contraction 7.24%
Lower Bollinger Band Walk Weakness 7.24%
New 52 Week Low Weakness 7.24%
Wide Bands Range Expansion 7.24%
Lower Bollinger Band Touch Weakness 7.24%
Oversold Stochastic Weakness 7.24%

   Recent Intraday Alerts

Alert Time
Rose Above Previous Day's High about 16 hours ago
Possible Inside Day about 18 hours ago
Down 2 % about 19 hours ago
Down 1% about 19 hours ago
Lower Bollinger Band Support about 19 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Biodexa Pharmaceuticals plc Description

Biodexa Pharmaceuticals Plc, a drug delivery technology company, focuses on the research and development of medicines in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTD219, a long-acting formulation of tacrolimus used to lower the risk of organ transplant rejection. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Disease Tumor Schizophrenia Drug Delivery Psoriasis Glioblastoma Major Depressive Disorder Brain Tumor Glioma Treatment Of Major Depressive Disorder Drug Delivery Technology Glioblastoma Multiforme Diffuse Intrinsic Pontine Glioma Organ Transplant

Is BDRX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 220.25
52 Week Low 3.5
Average Volume 206,231
200-Day Moving Average 20.10
50-Day Moving Average 6.35
20-Day Moving Average 5.34
10-Day Moving Average 4.54
Average True Range 0.65
RSI (14) 32.89
ADX 28.43
+DI 17.71
-DI 32.56
Chandelier Exit (Long, 3 ATRs) 5.49
Chandelier Exit (Short, 3 ATRs) 5.46
Upper Bollinger Bands 7.32
Lower Bollinger Band 3.37
Percent B (%b) 0.12
BandWidth 73.94
MACD Line -0.83
MACD Signal Line -0.71
MACD Histogram -0.1169
Fundamentals Value
Market Cap 10.09 Million
Num Shares 2.62 Million
EPS -873.22
Price-to-Earnings (P/E) Ratio 0.00
Price-to-Sales 7.13
Price-to-Book 0.51
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.36
Resistance 3 (R3) 4.30 4.08 4.27
Resistance 2 (R2) 4.08 3.95 4.10 4.24
Resistance 1 (R1) 3.96 3.87 4.02 4.02 4.22
Pivot Point 3.74 3.74 3.77 3.77 3.74
Support 1 (S1) 3.62 3.61 3.68 3.68 3.48
Support 2 (S2) 3.40 3.53 3.43 3.46
Support 3 (S3) 3.29 3.40 3.43
Support 4 (S4) 3.34